MSF reiterates call for BioNTech to urgently transfer mRNA vaccine technology to WHO mRNA technology transfer hub in South Africa as well as manufacturers in low- and middle-income countries, as faster option.

MSF reiterates its commitment to diagnosing and treating life-threatening NTDs in humanitarian settings as it signs the Kigali Declaration

MSF is disappointed in the inadequate outcome after nearly two years of discussions at the WTO  

Civil society letter to Trade Ministers at the World Trade Organization (WTO) on real TRIPS Waiver

The People's Vaccine Alliance, Oxfam, Section27 of South Africa, MSF, and more than 150 CSOs called on Trade Ministers at the WTO not to accept the current draft of the Ministerial Decision on the TRIPS Agreement and demand a real ...

Governments negotiating at the WTO must stand strong against problematic draft decision text at ministerial conference and work to agree on a real Waiver

To effectively increase people’s access to all COVID medical tools, governments must return to TRIPS Waiver proposed over 20 months ago

On the eve of BioNTech’s annual shareholder meeting, where the German pharmaceutical corporation is expected to report billions of euros in profits from COVID vaccine sales, MSF urged the German government, which supported BioNTech’s ...

Recommendations to countries and the WHO to ensure that treatment options are accessible and affordable for people living with diabetes.

MSF activities at the 75th session of the World Health Assembly (WHA), 22-28 May 2022.

How can disclosing clinical trial costs increase access to medical products?

Draft text is NOT the intellectual property Waiver for COVID-19 medical tools people need

The World Health Organization (WHO) announced global treatment guidance with new, safer and more effective six-month oral treatment regimen for multidrug-resistant tuberculosis.

Ahead of Moderna’s annual shareholder meeting, MSF again called on the US pharmaceutical corporation to urgently make mRNA vaccine technology available to manufacturers in low- and middle-income countries.

MSF urges all countries to adopt the guidelines and outlines the actions needed to make the WHO-recommended treatment accessible to people who need it

MSF authors analyse R&D and regulatory approval of DR-TB drugs bedaquiline and delamanid, and impact on treatment outcomes and access.

Draft text is NOT the intellectual property Waiver for COVID-19 medical tools people need